OncoSil Medical (ASX:OSL) has capped a significant year with major regulatory approvals, clinical trial progress, and expanding commercial traction for its brachytherapy device in pancreatic cancer.
OncoSil secures regulatory wins and expands global footprint in 2025
August 31, 2025 Australian Biotech
Latest Video
New Stories
-
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News -
Young NZ cancer patients to get funded medicines no matter where they are treated
October 6, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 - - Latest News -
TGA approves Roche's refillable eye implant for wet macular degeneration
October 5, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News
